CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel
- PMID: 27045981
- DOI: 10.1016/j.colsurfb.2016.03.075
CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel
Abstract
This combinational therapy is mainly aimed for complete eradication of tumor by killing both cancer cells and cancer stem cells. Salinomycin (SLM) was targeted towards cancer stem cells whereas paclitaxel (PTX) was used to kill cancer cells. Drug loaded poly (lactic-co-glycolic acid) nanoparticles were prepared by emulsion solvent diffusion method using cationic stabilizer. Size of the nanoparticles (below 150nm) was determined by dynamic light scattering technique and transmission electron microscopy. In vitro release study confirmed the sustained release pattern of SLM and PTX from nanoparticles more than a month. Cytotoxicity studies on MCF-7 cells revealed the toxicity potential of nanoparticles over drug solutions. Hyaluronic acid (HA) was coated onto the surface of SLM nanoparticles for targeting CD44 receptors over expressed on cancer stem cells and they showed the highest cytotoxicity with minimum IC50 on breast cancer cells. Synergistic cytotoxic effect was also observed with combination of nanoparticles. Cell uptake studies were carried out using FITC loaded nanoparticles. These particles showed improved cellular uptake over FITC solution and HA coating further enhanced the effect by 1.5 folds. CD44 binding efficiency of nanoparticles was studied by staining MDA-MB-231 cells with anti CD44 human antibody and CD44(+) cells were enumerated using flow cytometry. CD44(+) cell count was drastically decreased when treated with HA coated SLM nanoparticles indicating their efficiency towards cancer stem cells. Combination of HA coated SLM nanoparticles and PTX nanoparticles showed the highest cytotoxicity against CD44(+) cells. Hence combinational therapy using conventional chemotherapeutic drug and cancer stem cell inhibitor could be a promising approach in overcoming cancer recurrence due to resistant cell population.
Keywords: CD44 receptors; Cancer stem cells; Combinational chemotherapy; Hyaluronic acid; Paclitaxel; Polymeric nanoparticles; Salinomycin.
Copyright © 2016. Published by Elsevier B.V.
Similar articles
-
Vitamin E-based redox-sensitive salinomycin prodrug-nanosystem with paclitaxel loaded for cancer targeted and combined chemotherapy.Colloids Surf B Biointerfaces. 2018 Dec 1;172:506-516. doi: 10.1016/j.colsurfb.2018.08.063. Epub 2018 Aug 29. Colloids Surf B Biointerfaces. 2018. PMID: 30212688
-
Development and mechanistic insight into enhanced cytotoxic potential of hyaluronic acid conjugated nanoparticles in CD44 overexpressing cancer cells.Eur J Pharm Sci. 2017 Jan 15;97:79-91. doi: 10.1016/j.ejps.2016.10.028. Epub 2016 Oct 29. Eur J Pharm Sci. 2017. PMID: 27989859
-
Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.Matrix Biol. 2017 May;59:3-22. doi: 10.1016/j.matbio.2016.10.001. Epub 2016 Oct 13. Matrix Biol. 2017. PMID: 27746219 Review.
-
Targeted and controlled drug delivery system loading artersunate for effective chemotherapy on CD44 overexpressing cancer cells.Arch Pharm Res. 2016 May;39(5):687-94. doi: 10.1007/s12272-016-0738-4. Epub 2016 Mar 25. Arch Pharm Res. 2016. PMID: 27015824
-
Cancer stem cells targeting agents--a review.Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4064-7. Eur Rev Med Pharmacol Sci. 2015. PMID: 26592827 Review.
Cited by
-
Nanocarrier - Mediated Salinomycin Delivery Induces Apoptosis and Alters EMT Phenomenon in Prostate Adenocarcinoma.AAPS PharmSciTech. 2024 May 9;25(5):104. doi: 10.1208/s12249-024-02817-7. AAPS PharmSciTech. 2024. PMID: 38724836
-
CD44: A New Prognostic Marker in Colorectal Cancer?Cancers (Basel). 2024 Apr 19;16(8):1569. doi: 10.3390/cancers16081569. Cancers (Basel). 2024. PMID: 38672650 Free PMC article. Review.
-
Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.Med Oncol. 2024 Apr 9;41(5):112. doi: 10.1007/s12032-024-02347-z. Med Oncol. 2024. PMID: 38592510 Review.
-
Targeting breast cancer stem cells directly to treat refractory breast cancer.Front Oncol. 2023 May 12;13:981247. doi: 10.3389/fonc.2023.981247. eCollection 2023. Front Oncol. 2023. PMID: 37251931 Free PMC article. Review.
-
Molecular basis of PIP2-dependent conformational switching of phosphorylated CD44 in binding FERM.Biophys J. 2023 Jul 11;122(13):2675-2685. doi: 10.1016/j.bpj.2023.05.021. Epub 2023 May 22. Biophys J. 2023. PMID: 37218130
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous